DalCor www.dalcorpharma.com
Founded 2015 · 19 employees on LinkedIn · 1 known investors
DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
Founders & leadership
FL
Fouzia Laghrissi-ThodeChief Executive Officer
MD
Michael DixonChief Financial Officer
TH
Therese HeinonenChief Development Officer
DS
Diane SullivanChief Commercial Officer
Investors · 1
Competitors · 5
by search overlapCapricor9 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Arecor8 shared keywordsArecor develops proprietary therapeutics for diabetes and other cardiometabolic diseases using its Arestat formulation and drug delivery technology platform. It also partners with pharmaceutical and medtech companies to improve therapeutic profiles.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
CeleCor Therapeutics7 shared keywordsCeleCor Therapeutics is developing zalunfiban, an investigational next-generation GPIIb/IIIa platelet inhibitor injected subcutaneously for the pre-hospital treatment of STEMI heart attacks at the first point of medical contact. The company focuses on improving acute myocardial infarction treatment.
Xylocor7 shared keywordsXyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Companies competing with DalCor www.dalcorpharma.com for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does DalCor www.dalcorpharma.com do?
- DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
- Who are DalCor www.dalcorpharma.com's investors?
- DalCor www.dalcorpharma.com's investors include Sanderling Ventures.